Skip to main content

Alexandra Dreyzin, MD

Search for Additional Doctors

Department

Select the department from the list

Specialties

Select the Doctor's Specialty

Return to Search
Alexandra Dreyzin, MD

Alexandra Dreyzin, MD

Staff Clinician/Assistant Research Physician

dreyzina@nih.gov
301-827-3491

Dr. Alexandra Dreyzin is a pediatric oncologist and a Staff Clinician in the Center for Cellular Engineering. She is working to integrate cell therapy manufacturing and clinical data to develop novel prognostic markers and improve CAR T-cell efficacy.

ScB, Brown University
MD, University of Pittsburgh School of Medicine
MS in Clinical Research, University of Pittsburgh School of Medicine
Pediatrics Residency, UPMC Children's Hospital of Pittsburgh
Hematology/Oncology Fellowship, Children's National Hospital

Dr. Dreyzin completed a combined MD and MS at the University of Pittsburgh, where she was part of the Clinical Scientist Training Program. She then completed residency in Pediatrics at the University of Pittsburgh Medical Center (UPMC) Children's Hospital and worked for several years as a pediatric community hospitalist.

She then moved to Washington, DC to pursue fellowship training in Pediatric Hematology/Oncology at Children's National Hospital. Her fellowship research brought her to the NIH, where she began working with the Center for Cellular Engineering as well as the Pediatric Oncology Branch.

She joined the Center for Cellular Engineering as a Staff Clinician in 2024, with an adjunct faculty role in the NCI Pediatric Oncology Branch. In her translational research, she seeks to integrate CAR T-cell characterization data with clinical data and to understand how CAR T-cell manufacturing methods can be modified to improve treatment outcomes.

  • Society for Immunotherapy of Cancer (SITC) Sparkathon, Class of 2024
  • Hyundai Hope on Wheels Young Investigator Award, 2023

Dreyzin A, Rankin AW, Luciani K, Gavrilova T, Shah NN. Overcoming the challenges of primary resistance and relapse after CAR-T cell therapy. Expert Rev Clin Immunol. 2024;20(7):745-763. doi:10.1080/1744666X.2024.2349738

Prochazkova M, Dreyzin A, Shao L, et al. Deciphering the importance of culture pH on CD22 CAR T-cells characteristics. J Transl Med. 2024;22(1):384. Published 2024 Apr 24. doi:10.1186/s12967-024-05197-5

Mamo T, Dreyzin A, Stroncek D, McKenna DH. Emerging Biomarkers for Monitoring Chimeric Antigen Receptor T-Cell Therapy. Clin Chem. 2024;70(1):116-127. doi:10.1093/clinchem/hvad179

Dreyzin A, Cheng J, Leitenberg D, Diab Y. Severe autoimmune lymphoproliferative syndrome phenotype in a pediatric patient with a germline FAS gene variant. Pediatr Blood Cancer. 2023 Jul;70(7):e30304. doi: 10.1002/pbc.30304. Epub 2023 Mar 28. PMID: 36975155

McNerney KO, Si Lim SJ, Ishikawa K, Dreyzin A, Vatsayan A, Chen JJ, et al. HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALL. Blood Adv. 2023 Jun 27;7(12):2758-2771

Dreyzin A, Panch SR, Shalabi H, et al. Cryopreserved anti-CD22 and bispecific anti-CD19/22 CAR T cells are as effective as freshly infused cells. Mol Ther Methods Clin Dev. 2022;28:51-61. Published 2022 Dec 7. doi:10.1016/j.omtm.2022.12.004